Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2016 September;58(3) > Panminerva Medica 2016 September;58(3):206-10

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLES   

Panminerva Medica 2016 September;58(3):206-10

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Detection of hTERT mRNA in peripheral blood and its implication for diagnosis of early stage postoperative endometrial cancer micrometastasis

Jing LIANG, Geping YIN, Ming CHEN, Aifang WU

Department of Gynecology, Jinan Military General Hospital, Jinan, China


PDF


BACKGROUND: The aim of this study was to examine the expression of human telomerase reverse transcriptase (hTERT) in peripheral blood of endometrial cancer (EC) patients before and after surgery, and explore its clinical implication for diagnosis of early stage postoperative EC micrometastases.
METHODS: Fluorescence quantitative polymerase chain reaction (FQ-PCR) was used to determine the expression level of hTERT mRNA in peripheral blood of 40 healthy controls, 40 patients with benign uterine diseases, and 56 EC patients before and after surgery. All data were analyzed using SPSS Statistics v.17.0 software.
RESULTS: hTERT mRNA in peripheral blood was positive in 57.1% of EC patients (32/56), which is significantly higher compared to 0.0% (0/40) in healthy controls (χ2=34.286, P=0.000) and 5.0% (2/40) in patients with benign uterine diseases (χ2=27.736, P=0.000). The 32 EC patients with positive hTERT mRNA expression included 16 cases of stage I~II, and 16 cases of stage III~IV. The relative expression level of hTERT mRNA is -4.0000±0.2401 for stage I~II, and -2.7107±0.1253 for stage III~IV. The relative expression level of hTERT mRNA was significantly higher in EC patients with at higher pathological stages (t=-14.398, P=0.000). hTERT mRNA positive expression rates in peripheral blood of EC patients before and after surgery were 57.1% (32/56) and 85.7% (48/56), respectively, which is significantly different (χ2=11.200, P=0.001).
CONCLUSIONS: hTERT can be used as a marker for diagnosis of endometrial cancer micrometastasis via blood, and therefore has important value in choosing postoperative adjunctive therapy for early stage endometrial cancer.

top of page